Ranitidine recall affects Australia

Move is part of global recalls following contamination concerns, says Novartis AG’s Sandoz division
Reuters Health Staff writer
orange oval tablets

A manufacturer of generic ranitidine is recalling multiple batches of film-coated tablets in Australia, after some tablets were found to be contaminated by a probable carcinogen.

The move by Novartis AG’s Sandoz division comes in the wake of a US and European investigation into the presence of the impurity N-nitrosodimethylamine in ranitidine.